Gelonghui April 2 | Zhenghai Biotech's April 1 online conference said that in 2023, active biological bone is mainly being verified for conversion, and the company has been keeping a close eye on changes in collection policies. Active biological bone production is nearing its end in the second half of the year, and the launch is imminent. The company has also formulated more targeted pricing and sales strategies in accordance with the policy. In the future, the company will also continue to track policy developments such as bidding and price limits that may be carried out in various regions.
正海生物：下半年活性生物骨转产接近尾声、上市在即
Zhenghai Biotech: Active biological bone conversion is nearing completion in the second half of the year, and marketing is imminent
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.